Search

Your search keyword '"Ahmad Mosallaei"' showing total 3 results
Start Over Author "Ahmad Mosallaei"
3 results on '"Ahmad Mosallaei"'

1. The comparison between effect of chemoradiation with weekly cisplatin with or without celecoxib in treatment of nasopharyngeal carcinoma: A phase III clinical trial

Author

Mohamad Mohammadianpanah, Sasan Razmjoo Ghalaee, Bijan Khademi, Amin Shafizadeh, Shapour Omidvari, Ahmad Mosallaei, Niloufar Ahmadloo, and Mansour Ansari

Subjects
Celecoxib, Chemotherapy, Nasopharyngeal carcinoma, Radiotherapy, Response rate, Otorhinolaryngology, RF1-547
Abstract

Introduction: Concurrent cisplatin-based chemoradiation is currently considered the treatment of choice for locoregional nasopharyngeal carcinoma. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor which can potentially enhance the effect of radiotherapy. The aim of this study was to determine the efficacy and safety of celecoxib in nasopharyngeal carcinoma. Materials and Methods: Patients with newly diagnosed locoregional nasopharyngeal carcinoma were included in this clinical trial study. The patients were assigned to receive 7 weeks concurrent chemoradiation with weekly cisplatin and either celecoxib 100 mg twice daily or placebo. After completion of chemoradiation, all patients received combined chemotherapy with cisplatin plus 5-Fu every 3 weeks for 3 cycles. Clinical response rates and treatment-related toxicity were the primary and secondary end-point of the study. Results: Total of 50 eligible patients with the median age of 43 years were enrolled in the trial. Overall (complete and partial) clinical response rate was 100% in both groups. Complete and partial clinical response rates were 64% and 36% in study group and 44% and 56% in control group respectively (P>0.25). There was no difference in terms of treatment-related toxicity rates between two groups. Conclusions: This clinical trial showed that addition of celecoxib 100 mg twice daily to concurrent chemoradiation does not increase the response rates and treatment-related toxicities in patients with locoregional nasopharyngeal carcinoma.

Published
2009

3. Amplification and expression of EGFR and ERBB2 in Wilms tumor

Author

Helmout Modjtahedi, Abbas Ghaderi, Farid Kosari, Hossein Soleymanpour, Abdol-Mohammad Kajbafzadeh, Mehdi Shahriari, Ahmad Mosallaei, Mohammad Vasei, Guido Sauter, Holger Moch, Oreineb Ale-booyeh, University of Zurich, and Vasei, M

Subjects
Male, Cancer Research, Adolescent, Receptor, ErbB-2, Transplantation, Heterologous, Mice, Nude, 610 Medicine & health, Biology, Wilms Tumor, Mice, 1311 Genetics, 10049 Institute of Pathology and Molecular Pathology, Gene duplication, Genetics, medicine, 1312 Molecular Biology, Animals, Humans, 1306 Cancer Research, Child, neoplasms, Molecular Biology, EGFR inhibitors, Retrospective Studies, Tissue microarray, medicine.diagnostic_test, Gene Amplification, Infant, Wilms' tumor, Genes, erbB-1, Genes, erbB-2, medicine.disease, Kidney Neoplasms, Transplantation, ErbB Receptors, MSH2, Tissue Array Analysis, Child, Preschool, Cancer research, Immunohistochemistry, Female, Fluorescence in situ hybridization
Abstract

Wilms tumor is one of the most common solid tumors in children. We evaluated expression and amplification of a number of genes and their prognostic significance in 45 patients with Wilms tumor, using tissue microarray technology. The expression of EGFR, ERBB2, MDM2, CCND1, MLH1, MSH2, TP53, and ABCB1 (alias MDR1) was studied by immunohistochemistry. Amplification of the EGFR, ERBB2, MDM2, CCND1, CTTN (previously EMS1), RAF1, MYC, FGF3 (previously INT2), WNT1, GLI1, CDK4, and NCOA3 (alias AIB1) genes was assessed by fluorescence in situ hybridization. Expression of EGFR was seen in 17 of the 45 cases (38%) but was not associated with gene amplification. The ERBB2 gene was neither overexpressed nor amplified in any case. Tissue microarray and immunohistochemistry analyses for ERBB2 in whole-tumor sections were also negative in all cases. Strong p53 reactivity was noted in blastemal cells in two cases with an unfavorable outcome. ABCB1 reactivity was seen in five cases with favorable histology and outcome. Only one case showed nuclear cyclin D1 positivity. All tumors showed MLH1 and MSH2 expression. All examined genes showed normal copy numbers. Unfavorable histology correlated with poor prognosis (P=0.03). There was no significant association between gene expression and prognosis. Overexpression of the EGFR gene in many Wilms tumor cases warrants further study to determine the therapeutic benefit of EGFR inhibitors in combination with other therapies in Wilms tumor patients.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results